HomeCompareGLADZ vs JNJ

GLADZ vs JNJ: Dividend Comparison 2026

GLADZ yields 5.76% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GLADZ wins by $28.3K in total portfolio value
10 years
GLADZ
GLADZ
● Live price
5.76%
Share price
$25.23
Annual div
$1.45
5Y div CAGR
20.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$58.6K
Annual income
$9,188.86
Full GLADZ calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — GLADZ vs JNJ

📍 GLADZ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGLADZJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GLADZ + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GLADZ pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GLADZ
Annual income on $10K today (after 15% tax)
$489.62/yr
After 10yr DRIP, annual income (after tax)
$7,810.53/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, GLADZ beats the other by $3,824.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GLADZ + JNJ for your $10,000?

GLADZ: 50%JNJ: 50%
100% JNJ50/50100% GLADZ
Portfolio after 10yr
$44.4K
Annual income
$6,939.13/yr
Blended yield
15.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GLADZ
No analyst data
Altman Z
0.6
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GLADZ buys
0
JNJ buys
0
No recent congressional trades found for GLADZ or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGLADZJNJ
Forward yield5.76%2.13%
Annual dividend / share$1.45$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR20.3%28%
Portfolio after 10y$58.6K$30.3K
Annual income after 10y$9,188.86$4,689.40
Total dividends collected$32.8K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GLADZ vs JNJ ($10,000, DRIP)

YearGLADZ PortfolioGLADZ Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,393$692.95$10,592$272.30+$801.00GLADZ
2$13,078$887.61$11,289$357.73+$1.8KGLADZ
3$15,139$1,145.54$12,123$472.89+$3.0KGLADZ
4$17,690$1,490.89$13,141$629.86+$4.5KGLADZ
5$20,887$1,958.62$14,408$846.81+$6.5KGLADZ
6$24,949$2,600.03$16,021$1,151.60+$8.9KGLADZ
7$30,187$3,491.73$18,122$1,588.22+$12.1KGLADZ
8$37,050$4,749.99$20,930$2,228.20+$16.1KGLADZ
9$46,198$6,554.57$24,792$3,191.91+$21.4KGLADZ
10$58,621$9,188.86$30,274$4,689.40+$28.3KGLADZ

GLADZ vs JNJ: Complete Analysis 2026

GLADZStock

Gladstone Capital is a specialty finance company that invests in debt securities consisting primarily of senior term loans, senior subordinated loans, and junior subordinated loans in small and medium sized companies, that meet certain criteria. The criteria can include some or all of the following: the potential for growth in cash flow, adequate assets for loan collateral, experienced management teams with significant ownership interest in the business, adequate capitalization, profitable operations based on the borrower's cash flow, reasonable capitalization of the borrower and the potential to realize appreciation and gain liquidity in our equity position, if any.

Full GLADZ Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this GLADZ vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GLADZ vs SCHDGLADZ vs JEPIGLADZ vs OGLADZ vs KOGLADZ vs MAINGLADZ vs ABBVGLADZ vs MRKGLADZ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.